Brief: Cstone Pharmaceuticals Records HY Loss For Period Rmb361.6 Mln
25/08/2022 11:24
Aug 25 (Reuters) - CStone Pharmaceuticals 2616.HK :
* HY LOSS FOR PERIOD RMB361.6 MILLION VERSUS LOSS OF
RMB773.9
MILLION
* HY REVENUE RMB261.8 MILLION VERSUS RMB79.4 MILLION
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026